Hormone therapy in climacteric. Varying research results on risks and benefits
Magnusson, C.; Persson, I.
Lakartidningen 94(13): 1176-1179
1997
ISSN/ISBN: 0023-7205 PMID: 9148053 Document Number: 475447
Document emailed within 1 workday
Related Documents
Kovacs, G.T.; Chick, P. 1990: Hormone replacement therapy at the menopause. the risks and benefits Australian Family Physician 19(1): 73Warren, M.P. 2010: Hormone therapy for menopausal symptoms: putting benefits and risks into perspective Journal of Family Practice 59(12): E1-E7
von Schoultz, B. 2002: Health symptom-free women do not need preventive hormone replacement therapy. The risks outweigh the benefits; a large trial prematurely interrupted in the USA Lakartidningen 99(34): 3276-3278
Asher, M.A. 1998: Research: risks, benefits, and responsibilities. Presidential address Spine 23(12): 1362-1366
Donát, J.; Havel, V.; Hanousek, L. 1983: Vaginal hormone cytology in the therapy of climacteric and postcastration syndrome Sbornik Vedeckych Praci Lekarske Fakulty Karlovy University V Hradci Kralove 26(2): 123-129
Chittacharoen, A.; Domhardt, R.; Manonai, J.; Theppisai, U.; Golbs, S. 2004: Alleviation of the climacteric symptoms with oral sequential hormone replacement therapy Journal of the Medical Association of Thailand 87(1): 1-7
Zylberberg, B.; Dormont, D. 1996: Biweekly menopausal substitutive hormone therapy: effects on climacteric and prevention of osteoporosis Contraception Fertilite Sexualite 24(12): 874-878
Taleghany, P. 1971: Cyclic hormone therapy in climacteric and menopausal women in Iran. Report of 600 cases International Surgery 56(2): 78-81
Goldenberg, S.M.; Mindt, M.Rivera.; Jimenez, T.Rocha.; Brouwer, K.C.; Miranda, S.Morales.; Fisher, C.B. 2015: Structural and Interpersonal Benefits and Risks of Participation in HIV Research: Perspectives of Female Sex Workers in Guatemala Ethics and Behavior 25(2): 97-114
Magnusson, C.; Weiderpass, E. 2001: Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer Lakartidningen 98(5): 418-421
Ro, K.G.; Anderson, H.V. 1990: Thrombolytic therapy in acute MI. Weighing the risks and benefits Postgraduate Medicine 88(8): 79-80 83-6 89-90 Passim
Tollemar, J.; Tydén, G.; Brattström, C.; Groth, C.G. 1988: Anticoagulation therapy for prevention of pancreatic graft thrombosis: benefits and risks Transplantation Proceedings 20(3): 479-480
Soriano, V.; Rivas, P.; Nuñez, M. 2008: Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 47(11): 1486-1489
Ouattara, E.N.; Anglaret, X.; Wong, A.Y.; Chu, J.; Hsu, H.E.; Danel, C.; Eholié, S.; Moh, R.; Gabillard, D.; Walensky, R.P.; Freedberg, K.A. 2012: Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age Aids 26(5): 625-634
Grassi, L. 1970: Results of therapy with extracts of cartilage and bone marrow in climacteric gonalgias Minerva Medica 61(38): 2080-2085
Kukin, M. 1978: Research with recombinant DNA: potential risks, potential benefits, and ethical considerations New York State Journal of Medicine 78(2): 226-235
Rosen, B.; Irvine, J.; Ritvo, P.; Shapiro, H.; Stewart, D.; Reynolds, K.; Robinson, G.; Thomas, J.; Neuman, J.; Murphy, J. 1997: The feasibility of assessing women's perceptions of the risks and benefits of fertility drug therapy in relation to ovarian cancer risk Fertility and Sterility 68(1): 90-94
Anglaret, X.; Scott, C.A.; Walensky, R.P.; Ouattara, E.; Losina, E.; Moh, R.; Becker, J.E.; Uhler, L.; Danel, C.; Messou, E.; Eholié, S.; Freedberg, K.A. 2013: Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? a model-based analysis Antiviral Therapy 18(1): 45-55
Panico, S.; Galasso, R.; Celentano, E.; Ambrosca, C.; Asti, A.; Frova, L.; Capocaccia, R.; Berrino, F. 1997: Hormone replacement therapy and cardiovascular diseases: different populations, different risks Annali Dell'istituto Superiore di Sanita 33(2): 203-206
Wahl, D.G.; Bounameaux, H.; de Moerloose, P.; Sarasin, F.P. 2000: Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis Archives of Internal Medicine 160(13): 2042-2048